赛马鲁肽
医学
杜拉鲁肽
内科学
2型糖尿病
糖尿病
胰高血糖素样肽-1
艾塞那肽
利拉鲁肽
重症监护医学
内分泌学
作者
Steven P. Marso,Stephen C. Bain,Agostino Consoli,Freddy Goldberg Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,Ole Paaske Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll
标识
DOI：10.1056/nejmoa1607141
摘要
Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI
rocky15
尹不愁
敬老院1号
寻道图强
紫金大萝卜
cctv18
升升升呀
可靠
Solomon
Lucas
互助遵法尚德
忍冬半夏
sutharsons
从容芮
汉堡包
糟糕的铁身
magical1991
英姑
英俊的铭
Ava
皖公网安备34019202002308
